Sign in
Taking people in South AfricaPhase 3

Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease

Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.

Key facts

Who runs it
Eli Lilly and Company
Where
Cape Town, Johannesburg, Paarl, Sommerset West, and Worcester, South AfricaSee the 5 sitesAlso in 38 other countries, 553 sites
Trial code
Registry title
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Status
Recruiting
Phase
Phase 3
People taking part
7,140 people, planned
Started
1 Dec 2025
Expected to end
Aug 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Orforglipron
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). It compares orforglipron with placebo and lasts about 5 years.

Age
50 years or older
Sex
All sexes can join
Disease stage
Established ASCVD and/or CKD

Main reasons for not taking part

  • Type 1 diabetes
  • A major heart condition within 60 days before screening
  • New York Heart Association Class IV heart failure

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Have established ASCVD and/or CKD

Who cannot take part

  • Have had a major heart condition within 60 days prior to screening
  • Have type 1 diabetes
  • Have New York Heart Association Functional Classification Class IV heart failure

This trial is currently available in South Africa.

Also in 38 other countries, 553 sites

  • Tread ResearchCape Town, South AfricaContact: Hans Prozesky (principal investigator)Taking people
  • Soweto Clinical Trials CentreJohannesburg, South AfricaContact: Qasim Bhorat (principal investigator)Not yet recruiting
  • Paarl Research CentrePaarl, South AfricaContact: Kathleen Coetzee (principal investigator)Taking people
  • Mediclinic VergelegenSommerset West, South AfricaContact: Johannes Engelbrecht (principal investigator)Taking people
  • Clinical Projects ResearchWorcester, South AfricaContact: Louis Van Zyl (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

The 2 groups in the trial

  • OrforglipronTreatment being tested

    Participants will receive orforglipron orally + standard of care

  • PlaceboPlacebo, for comparison

    Participants will receive placebo orally + standard of care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Plain-language title
Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026